Quantcast

Amyotrophic Lateral Sclerosis (ALS) Market Spotlight, 2019 Edition – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Market
Spotlight: Amyotrophic Lateral Sclerosis (ALS)”
report has been
added to ResearchAndMarkets.com’s offering.

This Market Spotlight report covers the Amyotrophic Lateral Sclerosis
(ALS) market, comprising key pipeline and marketed drugs, clinical
trials, upcoming and regulatory events, patent information, a 10-year
disease prevalence forecast, and licensing and acquisition deals, as
well as presenting drug-specific revenue forecasts

Key Takeaways

  • The report estimates that in 2017, there were 47,190 incident cases of
    amyotrophic lateral sclerosis (ALS) in adults aged 40 years and older
    worldwide, and forecasts that number to increase to 56,070 incident
    cases by 2026.
  • Oceania and Europe are estimated to have the highest disease incidence
    (2.33 and 2.16 cases per 100,000 people, respectively), while Asia and
    Africa have the lowest incidence (0.62 and 0.89 cases per 100,000
    people, respectively).
  • Italfarmaco’s Tiglutik, Mitsubishi Tanabe’s Radicava, Advanz’s
    Rilutek, and Corestem’s Neuronata-R are the only marketed drugs
    available for ALS. These drugs are administered via the intravenous
    and oral routes.
  • The greatest proportion of industry-sponsored drugs in active clinical
    development for ALS are in Phase II, with only one drug in the NDA/BLA
    phase.
  • Therapies in mid-to-late-stage development for ALS focus on a wide
    variety of targets. The most popular method of administration is the
    oral route.
  • High-impact upcoming events for drugs in the ALS space comprise
    topline Phase II and Phase III trial results for a number of drugs, an
    expected PDUFA date for BHV-0223, and an expected CHMP opinion for
    Radicava.
  • The overall likelihood of approval of a Phase I ALS asset is 5.3%, and
    the average probability a drug advances from Phase III is 33.3%.
    Drugs, on average, take 7.9 years from Phase I to approval, compared
    to 9.6 years in the overall neurology space.
  • There have been 24 licensing and asset acquisition deals involving ALS
    drugs during 2014-19. The $1,225m exclusive collaboration and license
    agreement signed in October 2018 between Denali and Sanofi to develop
    and commercialize products containing receptor-interacting
    serine/threonine-protein kinase 1 (RIPK1) inhibitors for neurological
    indications such as Alzheimer’s disease, ALS, and multiple sclerosis
    was the largest deal during the period.
  • The distribution of clinical trials across Phase I-IV indicates that
    the majority of trials for ALS have been in the early and midphases of
    development, with 81% of trials in Phase I-II, and only 19% in Phase
    III-IV.
  • The US has a substantial lead in the number of ALS clinical trials
    globally. The UK leads the major EU markets, while Japan has the top
    spot in Asia.
  • Clinical trial activity in the ALS space is dominated by completed
    trials. Otsuka/Avanir have the highest number of completed clinical
    trials for ALS, with 11 trials.
  • Biogen leads industry sponsors with the highest number of clinical
    trials for ALS.

Key Topics Covered:

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

Subtypes

TREATMENT

Symptomatic treatments

Ventilatory management

Nutritional management

Disease-modifying therapies

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

Masitinib for ALS (May 28, 2018)

NP001 for ALS (April 26, 2018)

IONIS-C9Rx for ALS (April 20, 2018)

IONIS-SOD1Rx for ALS (April 20, 2018)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

ITF Pharma Plans October US Roll-Out Of Liquid Riluzole Formulation For
ALS

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

Sanofi Stumps Up $125m To Access Denali RIPK1 Inhibitors

Celgene Options Neuro Candidates From Skyhawk, Participates In Series A
Round

$27.5m For AliveGen Neuromuscular Candidates

Celgene Further Commits To Neuroscience With Prothena Pact

A Deal For Biogen, But Not The One Investors Are Waiting For

Deal Watch: Pfizer Begins 2018 With Two Deals, Including ALS Tie-Up With
Sangamo

PARENT PATENTS

CLINICAL TRIAL LANDSCAPE

Sponsors by status

Sponsors by phase

Recent events

BIBLIOGRAPHY

Prescription information

For more information about this report visit https://www.researchandmarkets.com/r/yjbq3h

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Central
Nervous System Drugs

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.